Skip to main content
Top
Published in: AIDS and Behavior 11/2018

01-11-2018 | Original Paper

The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men

Authors: Megha L. Mehrotra, K. Rivet Amico, Vanessa McMahan, David V. Glidden, Patricia Defechereux, Juan V. Guanira, Robert M. Grant

Published in: AIDS and Behavior | Issue 11/2018

Login to get access

Abstract

Qualitative studies suggest that social relationships play an important role in HIV pre-exposure prophylaxis (PrEP) use, but there have been few quantitative assessments of the role of social relationships in PrEP uptake or adherence. We examined the association between disclosure of study participation or LGBT identity and PrEP use in the 1603 HIV-negative participants enrolled in the iPrEx OLE study. We also evaluated the association between LGBT social group involvement and PrEP use. Study participation disclosure to parents and LGBT identity disclosure to anyone in a participant’s social network were associated with greater PrEP uptake. Study participation disclosure to partners was associated with higher probability of having protective PrEP drug concentrations compared [risk difference 0.15 95% CI (0.01, 0.30)]. For each additional type of LGBT organization a participant was involved in, the probability of PrEP uptake and having protective drug concentrations increased by 0.04 [95% CI (0.03, 0.06)] and 0.04 (95% CI (0.02, 0.07)] respectively. Overall, social context was associated with PrEP use in iPrEx OLE, and should be taken into consideration when designing future PrEP implementation programs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc. 2015;18:3.CrossRef Hankins C, Macklin R, Warren M. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. J Int AIDS Soc. 2015;18:3.CrossRef
2.
go back to reference Eaton LA, Kalichman S. Translating Pre-Exposure Prophylaxis Evidence into Practice and Public Health Impact. In: Advances Biomedical, editor. Biomedical advances in HIV prevention: social and behavioral perspectives. New York: Springer Science & Business Media; 2013. Eaton LA, Kalichman S. Translating Pre-Exposure Prophylaxis Evidence into Practice and Public Health Impact. In: Advances Biomedical, editor. Biomedical advances in HIV prevention: social and behavioral perspectives. New York: Springer Science & Business Media; 2013.
3.
go back to reference Sorensen G, et al. Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations. Prev Med. 2003;37:188–97.CrossRef Sorensen G, et al. Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations. Prev Med. 2003;37:188–97.CrossRef
4.
go back to reference Berkman LF, Syme SL. Social networks, host resistance, and mortality: A nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979;109:186–204.CrossRef Berkman LF, Syme SL. Social networks, host resistance, and mortality: A nine-year follow-up study of Alameda County residents. Am J Epidemiol. 1979;109:186–204.CrossRef
5.
6.
go back to reference Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29:377–87.CrossRef Uchino BN. Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med. 2006;29:377–87.CrossRef
7.
go back to reference Gottlieb BH, Bergen AE. Social support concepts and measures. J Psychosom Res. 2010;69:511–20.CrossRef Gottlieb BH, Bergen AE. Social support concepts and measures. J Psychosom Res. 2010;69:511–20.CrossRef
8.
go back to reference Kumar S, Calvo R, Avendano M, Sivaramakrishnan K, Berkman LF. Social support, volunteering and health around the world: cross-national evidence from 139 countries. Soc Sci Med. 2012;1982(74):696–706.CrossRef Kumar S, Calvo R, Avendano M, Sivaramakrishnan K, Berkman LF. Social support, volunteering and health around the world: cross-national evidence from 139 countries. Soc Sci Med. 2012;1982(74):696–706.CrossRef
9.
go back to reference DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207–18.CrossRef DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23:207–18.CrossRef
10.
go back to reference Ware NC, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr. 2012;1999:59. Ware NC, et al. What’s love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV serodiscordant couples. J Acquir Immune Defic Syndr. 2012;1999:59.
11.
go back to reference Liu A, et al. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014;1999(67):528–37.CrossRef Liu A, et al. Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study. J Acquir Immune Defic Syndr. 2014;1999(67):528–37.CrossRef
12.
go back to reference Donnell D, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;1999(66):340–8.CrossRef Donnell D, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;1999(66):340–8.CrossRef
13.
go back to reference Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.CrossRef Haberer JE, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511.CrossRef
14.
go back to reference Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;1999(63 Suppl 2):S122–9.CrossRef Baeten JM, Haberer JE, Liu AY, Sista N. Preexposure prophylaxis for HIV prevention: where have we been and where are we going? J Acquir Immune Defic Syndr. 2013;1999(63 Suppl 2):S122–9.CrossRef
15.
go back to reference Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.CrossRef Grant RM, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.CrossRef
16.
go back to reference Amico KR, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in cape town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21:1361–75.CrossRef Amico KR, et al. Experiences with HPTN 067/ADAPT study-provided open-label PrEP among women in cape town: facilitators and barriers within a mutuality framework. AIDS Behav. 2017;21:1361–75.CrossRef
17.
go back to reference Gilmore HJ, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs. 2013;27:560–6.CrossRef Gilmore HJ, et al. Participant experiences and facilitators and barriers to pill use among men who have sex with men in the iPrEx pre-exposure prophylaxis trial in San Francisco. AIDS Patient Care STDs. 2013;27:560–6.CrossRef
18.
go back to reference Arnold T, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12:e0172354.CrossRef Arnold T, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS ONE. 2017;12:e0172354.CrossRef
19.
go back to reference Goicochea, P. Barriers and facilitators to PrEP adherence in iPrEx: a prevention trial that started in 3 Andean cities. (2009). Goicochea, P. Barriers and facilitators to PrEP adherence in iPrEx: a prevention trial that started in 3 Andean cities. (2009).
20.
go back to reference Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium☆☆This paper is adapted from Berkman LF, Glass T. Social integration, social networks, social support and health. In Berkman LF, Kawachi I, Social Epidemiology. New York: Oxford University Press; and Brissette I, Cohen S, Seeman T. Measuring social integration and social networks. In Cohen S, Underwood L, Gottlieb B, Social Support Measurements and Intervention. New York: Oxford University Press. Soc Sci Med 51: 843–857 (2000). Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium☆☆This paper is adapted from Berkman LF, Glass T. Social integration, social networks, social support and health. In Berkman LF, Kawachi I, Social Epidemiology. New York: Oxford University Press; and Brissette I, Cohen S, Seeman T. Measuring social integration and social networks. In Cohen S, Underwood L, Gottlieb B, Social Support Measurements and Intervention. New York: Oxford University Press. Soc Sci Med 51: 843–857 (2000).
21.
go back to reference Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.CrossRef
22.
go back to reference Hosek SG, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;1999(62):447–56.CrossRef Hosek SG, et al. The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr. 2013;1999(62):447–56.CrossRef
23.
go back to reference Grohskopf LA, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;1999(64):79–86.CrossRef Grohskopf LA, et al. Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013;1999(64):79–86.CrossRef
24.
go back to reference Castillo-Mancilla J, et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60:6692–7.CrossRef Castillo-Mancilla J, et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob Agents Chemother. 2016;60:6692–7.CrossRef
25.
go back to reference Anderson PL, et al. Emtricitabine–Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151.CrossRef Anderson PL, et al. Emtricitabine–Tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151.CrossRef
27.
go back to reference Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol. 2007;60:874–82.CrossRef Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from multivariable logistic regression. J Clin Epidemiol. 2007;60:874–82.CrossRef
28.
go back to reference Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12:308–31. Williams R. Using the margins command to estimate and interpret adjusted predictions and marginal effects. Stata J. 2012;12:308–31.
29.
go back to reference STATA Statistical Software: Release 13. (StataCorp LP). STATA Statistical Software: Release 13. (StataCorp LP).
30.
go back to reference Tangmunkongvorakul A, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25:961–7.CrossRef Tangmunkongvorakul A, et al. Facilitators and barriers to medication adherence in an HIV prevention study among men who have sex with men in the iPrEx study in Chiang Mai, Thailand. AIDS Care. 2013;25:961–7.CrossRef
31.
go back to reference Galea JT, et al. Acceptability of Pre-Exposure Prophylaxis (PrEP) as an HIV prevention strategy: barriers and facilitators to PrEP uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256–62.CrossRef Galea JT, et al. Acceptability of Pre-Exposure Prophylaxis (PrEP) as an HIV prevention strategy: barriers and facilitators to PrEP uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22:256–62.CrossRef
Metadata
Title
The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men
Authors
Megha L. Mehrotra
K. Rivet Amico
Vanessa McMahan
David V. Glidden
Patricia Defechereux
Juan V. Guanira
Robert M. Grant
Publication date
01-11-2018
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2018
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-2151-0

Other articles of this Issue 11/2018

AIDS and Behavior 11/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.